[go: up one dir, main page]

BR0110112A - Derivados de pirrolidina e piperidina e seu uso para o tratamento de distúrbios neurodegenerativos - Google Patents

Derivados de pirrolidina e piperidina e seu uso para o tratamento de distúrbios neurodegenerativos

Info

Publication number
BR0110112A
BR0110112A BR0110112-9A BR0110112A BR0110112A BR 0110112 A BR0110112 A BR 0110112A BR 0110112 A BR0110112 A BR 0110112A BR 0110112 A BR0110112 A BR 0110112A
Authority
BR
Brazil
Prior art keywords
hydroxy
bond
treatment
lower alkoxy
chr
Prior art date
Application number
BR0110112-9A
Other languages
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0110112A publication Critical patent/BR0110112A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"DERIVADOS DE PIRROLIDINA E PIPERIDINA E SEU USO PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS". A invenção refere-se a compostos de fórmula (I) em que Ar^ 1^ é piridila ou fenila, substituída por hidróxi, alquila inferior, halogênio, amino, nitro, benzilóxi ou alcóxi inferior - alcóxi inferior, ou é o grupo (a), em que Z^ 1^ é um anel heterocíclico de cinco elementos, que contém um ou dois heteroátomos, selecionados dentre N ou O; R^ 1^ é hidrogênio, hidróxi ou um grupo oxo; Ar^ 2^ é piridila ou fenila, opcionalmente substituída por hidróxi, alquila inferior, halogênio, amino, nitro, benzilóxi ou alcóxi inferior - alcóxi inferior, ou é o grupo (b), em que Z^ 2^ é um anel de cinco ou seis elementos, que contém, opcionalmente, um ou dois heteroátomos, selecionados dentre N ou O; e Q é -S-, -S (O) - ou -S (O)~ 2~-; X é uma ligação, -CH (OH) - ou - (CH~ 2~)~ n~-; A é uma ligação ou - (CHR)~ m~-; R é hidrogênio, halogênio ou hidróxi, independentemente um do outro se m é 2 ou 3; Y é - (CR~ 2~)~ m~-, -O-, -C=C-, -C<154>C-, piperidin-1-ila, pirrolidin-1-ila OU C~ 4~-C~ 6~-cicloalquila, cujos anéis são opcionalmente substituídos por hidróxi; B é uma ligação, -O- ou - (CHR)~ m~-; n é 1 ou 2; e m é 1 a 3; e sais de adição de ácido farmaceuticamente aceitáveis dos mesmos, com a exceção de compostos, em que A e B são simultaneamente uma ligação e Y é -CHR-. Os compostos podem ser usados no tratamento de doenças neurodegenerativas.
BR0110112-9A 2000-04-20 2001-04-11 Derivados de pirrolidina e piperidina e seu uso para o tratamento de distúrbios neurodegenerativos BR0110112A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108610 2000-04-20
PCT/EP2001/004171 WO2001081303A1 (en) 2000-04-20 2001-04-11 Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BR0110112A true BR0110112A (pt) 2003-02-11

Family

ID=8168522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110112-9A BR0110112A (pt) 2000-04-20 2001-04-11 Derivados de pirrolidina e piperidina e seu uso para o tratamento de distúrbios neurodegenerativos

Country Status (18)

Country Link
US (1) US6451819B2 (pt)
EP (1) EP1278728B1 (pt)
JP (1) JP4219590B2 (pt)
KR (1) KR100501606B1 (pt)
CN (1) CN1178911C (pt)
AR (1) AR028343A1 (pt)
AT (1) ATE274494T1 (pt)
AU (2) AU2001273942B2 (pt)
BR (1) BR0110112A (pt)
CA (1) CA2404464C (pt)
DE (1) DE60105144T2 (pt)
ES (1) ES2225553T3 (pt)
MX (1) MXPA02010261A (pt)
PE (1) PE20011185A1 (pt)
PT (1) PT1278728E (pt)
TR (1) TR200402442T4 (pt)
WO (1) WO2001081303A1 (pt)
ZA (1) ZA200208015B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326777C (en) * 1998-04-01 2011-12-20 Nortran Pharmaceuticals Inc. Aminocyclohexyl ether compounds and uses thereof
US6979685B1 (en) * 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
US6885903B2 (en) * 2001-07-10 2005-04-26 General Electric Company Method and system for tracking repair of components
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US7866517B2 (en) * 2002-10-31 2011-01-11 Fabio Pedrini Vehicle-mounted equipment carrier
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
ATE325789T1 (de) * 2003-05-02 2006-06-15 Cardiome Pharma Corp Aminocyclohexylether-verbindungen und deren verwendung
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US8058304B2 (en) * 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
JP5583325B2 (ja) * 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
NZ588698A (en) * 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2370451B1 (en) 2008-12-02 2016-11-16 Wave Life Sciences Japan, Inc. Method for the synthesis of phosphorus atom modified nucleic acids
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
US10428019B2 (en) * 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
AU2015287663B2 (en) * 2014-07-10 2019-02-28 SpecGx LLC Process for preparing substituted phenylalkanes
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74140A (en) * 1984-04-10 1988-05-31 Robins Co Inc A H Substituted n-((amino)alkyl)-1-pyrrolidine,-1-piperidine and-1-homopiperidine-carboxamides and pharmaceutical compositions containing them
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
MXPA02010261A (es) 2003-04-25
DE60105144D1 (de) 2004-09-30
ATE274494T1 (de) 2004-09-15
KR100501606B1 (ko) 2005-07-18
CN1425002A (zh) 2003-06-18
CA2404464C (en) 2008-03-11
CA2404464A1 (en) 2001-11-01
ZA200208015B (en) 2004-02-10
WO2001081303A1 (en) 2001-11-01
AU7394201A (en) 2001-11-07
PE20011185A1 (es) 2001-11-14
ES2225553T3 (es) 2005-03-16
JP4219590B2 (ja) 2009-02-04
US20010047031A1 (en) 2001-11-29
TR200402442T4 (tr) 2004-12-21
KR20030013387A (ko) 2003-02-14
AU2001273942B2 (en) 2005-09-01
PT1278728E (pt) 2004-10-29
JP2003531190A (ja) 2003-10-21
EP1278728B1 (en) 2004-08-25
US6451819B2 (en) 2002-09-17
CN1178911C (zh) 2004-12-08
DE60105144T2 (de) 2005-09-08
EP1278728A1 (en) 2003-01-29
AR028343A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
BR0110112A (pt) Derivados de pirrolidina e piperidina e seu uso para o tratamento de distúrbios neurodegenerativos
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA200100766A1 (ru) Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
BRPI0418102A (pt) derivados de quinolina
BR0113519A (pt) Heterociclos bicìclicos, composições farmacêuticas contendo esses compostos, seu uso e processos para sua preparação
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
TR200400238T4 (tr) &#39;&#39;Perindopril tert-bütilamin tuzunun alfa kristalin şekli&#39;&#39;
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
ATE387199T1 (de) Neue substanzen und verbindungen als protease- inhibitoren
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
DE60130771D1 (de) Substituierte heterocyclische amide
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
BR9910119A (pt) Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina
EP3021843A2 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EA200300071A1 (ru) Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина
EA200600513A1 (ru) Бициклические [3.1.0] производные в качестве ингибиторов переносчиков глицина
Jin et al. SAR and molecular mechanism study of novel acylhydrazone compounds targeting HIV-1 CA
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2082 DE 30/11/2010.